Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: A power quality control circuit is connected to monitor an AC input power and selectively connect the AC input power through a contactor. The power quality control circuit includes power quality monitor circuitry that determines whether the AC input power has an overfrequency condition, an underfrequency condition, an overvoltage condition or an undervoltage condition, and prevents closing of the contactor in response to a determination of any of those conditions.

Abstract: A system, method, and computer readable medium directed to communication with a remote component in an aircraft environment are described. The system includes the remote component in the aircraft environment to control a single phase alternating or direct current input drawn from a constant voltage power source, and a controller in the aircraft environment configured to monitor the current input to the remote component and determine a message from the remote component based on a current pattern in the current input.

Abstract: A power distribution system includes multiple uniform power distribution modules and multiple uniform mating connectors. A portion of the mating connectors are connected to the power distribution modules directly and the remainder are connected to the power distribution modules via a ground fault interrupt adapter.

Abstract: A system, method, and computer readable medium directed to communication with a remote component in an aircraft environment are described. The system includes the remote component in the aircraft environment to control a single phase alternating or direct current input drawn from a constant voltage power source, and a controller in the aircraft environment configured to monitor the current input to the remote component and determine a message from the remote component based on a current pattern in the current input.

Abstract: A front end structure for a vehicle includes a fascia member defining a forward end of an engine compartment of the vehicle and a radiator disposed in the engine compartment rearwardly spaced from the fascia member. At least one structural brace extends from a location at or near an underside of the vehicle to a location at or near an upper end of the engine compartment. A duct member is interposed between the fascia member and the radiator. The duct member at least partially blocks the radiator and defines a duct passage extending from an underside opening of the vehicle to the radiator. The duct member has at least one recess defined therein that receives the at least one structural brace.

Abstract: A front end structure for a vehicle includes a facia member defining a forward end of an engine compartment of the vehicle and a radiator disposed in the engine compartment rearwardly spaced from the facia member. A duct member is interposed between the facia member and the radiator. The duct member at least partially blocks the radiator and defines a duct passage extending from an underside opening of the vehicle to the radiator. At least one duct opening is defined in the duct member for supplementing air flow to the radiator from the underside opening.

Abstract: A power distribution system includes multiple uniform power distribution modules and multiple uniform mating connectors. A portion of the mating connectors are connected to the power distribution modules directly and the remainder are connected to the power distribution modules via a ground fault interrupt adapter.

Abstract: A modified air dam includes an integral spring-like, corrugate-shaped portion for absorbing impact forces imposed on the air dam. A lower portion of the air dam is generally planar and angled slightly from a vertical plane toward the front of the vehicle. The air dam also includes a rounded portion to provide a horizontal offset between upper and lower portions of the air dam and to direct airflow toward a bottom portion of the radiator. The air dam may also be curved side-to-side or employ an inverted, generally U-shaped portion as a first force absorbing region and a spaced rib that serves as a second force absorbing region. The generally U-shaped portion also advantageously extends over a fastener and mounting region of the air dam.

Abstract: The present invention provides a scalable process for the preparation of stilbenes by (i) condensing 3,5-dialkylbenzyl phosphonates with 4?-O-tetrahydropyranyl benzaldehyde to get 3,5-alkyl-4?-O-tetrahydropyranyl Stilbene and (ii) deprotecting the obtained 3,5-Dialkyl-4?-O-tetrahydropyranylstilbene to yield stilbenes. The present invention also provides a novel intermediate 3,5-Dialkyl-4?-O-tetrahydropyranyl stilbene, which is a key intermediate for the synthesis of stilbenes such as Pterostilbene and Resveratrol. The present invention also provides characteristics of various solid forms of Pterostilbene, methods for their preparation, as well as dosage forms containing the same for administration to or consumption by humans.

Abstract: A front end structure for a vehicle includes a fascia member defining a forward end of an engine compartment of the vehicle and a radiator disposed in the engine compartment rearwardly spaced from the fascia member. At least one structural brace extends from a location at or near an underside of the vehicle to a location at or near an upper end of the engine compartment. A duct member is interposed between the fascia member and the radiator. The duct member at least partially blocks the radiator and defines a duct passage extending from an underside opening of the vehicle to the radiator. The duct member has at least one recess defined therein that receives the at least one structural brace.

Abstract: A front end structure for a vehicle includes a facia member defining a forward end of an engine compartment of the vehicle and a radiator disposed in the engine compartment rearwardly spaced from the facia member. A duct member is interposed between the facia member and the radiator. The duct member at least partially blocks the radiator and defines a duct passage extending from an underside opening of the vehicle to the radiator. At least one duct opening is defined in the duct member for supplementing air flow to the radiator from the underside opening.

Abstract: A modified air dam includes an integral spring-like, corrugate-shaped portion for absorbing impact forces imposed on the air dam. A lower portion of the air dam is generally planar and angled slightly from a vertical plane toward the front of the vehicle. The air dam also includes a rounded portion to provide a horizontal offset between upper and lower portions of the air dam and to direct airflow toward a bottom portion of the radiator. The air dam may also be curved side-to-side or employ an inverted, generally U-shaped portion as a first force absorbing region and a spaced rib that serves as a second force absorbing region. The generally U-shaped portion also advantageously extends over a fastener and mounting region of the air dam.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.